Design Therapeutics (DSGN) Assets Average (2021 - 2026)

Design Therapeutics has reported Assets Average for 6 years, with the latest figure at $222.8 million in Q2 2026.

• Assets Average for Q2 2026 came in at $222.8 million, down 3.21% year-over-year; the trailing twelve-month figure through Jun 2026 was $222.8 million (down 3.21% YoY), and the FY2025 annual result was $239.1 million, down 11.71% from the prior year.
• Assets Average eased to $222.8 million in Q2 2026, from $228.3 million in the prior quarter.
• Over five years, Assets Average peaked at $384.7 million in Q1 2022 and troughed at $217.3 million in Q3 2025.
• A 5-year average of $286.8 million and a median of $279.2 million in 2024 frame the typical range for Assets Average.
• The widest annual swing landed in 2022, when Assets Average surged 71.59%; it then declined 18.18% in 2025.
• A 5-year view of Assets Average shows it stood at $347.9 million in 2022, then slipped by 15.26% to $294.8 million in 2023, then decreased by 12.86% to $256.9 million in 2024, then declined by 14.75% to $219.0 million in 2025, then grew by 1.73% to $222.8 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $222.8 million in Q2 2026, $228.3 million in Q1 2026, and $219.0 million in Q4 2025.